MedPath

Efficacy in Alveolar Bone Regeneration With Autologous MSCs and Biomaterial in Comparison to Autologous Bone Grafting

Phase 3
Recruiting
Conditions
Alveolar Bone Atrophy
Interventions
Procedure: Autologous bone graft
Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial)
Registration Number
NCT04297813
Lead Sponsor
University of Bergen
Brief Summary

A randomized controlled clinical multi center trial to assess the efficacy of a combination of autologous mesenchymal stem cells and biomaterial in jaw bone regeneration prior to dental implant placement in comparison to standard autologous bone block grafting.

Detailed Description

A phase III multi center clinical trial, randomized and controlled.The study subject is lacking one or more sheet behind the canine in the upper or lower jaw, and the alveolar ridge is too narrow to place a dental implant. The test objects will have augmentation using autologous mesenchymal stromal cells and a biomaterial, biphasic Calcium Phosphate. The control is the traditional bone block from the ramus.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Healthy, non smoking patients in need of dental implants in the upper or lower jaw, with loss in vertical height and less that 4 mm in lateral width.
Exclusion Criteria
  • General contraindications for dental and/or surgical treatments
  • Contraindications for both bone marrow harvesting and bone grafts
  • History of any malignant diseases
  • Concurrent or previous radiotherapy of head and neck region
  • History of contagious diseases (HIV, HTLV and/or syphilis seropositivity, hepatitis B or C infection)
  • Uncontrolled diabetes mellitis, e.g. patients with diabetes not regulated with medications or diet. This will be verified based on patient's history and concurrent HbA1c levels (HbA1c > 53 mmol/mol).
  • Inflammatory and autoimmune disease of the oral cavity.
  • Concurrent or previous immunosuppressant, bisphosphonate or high dose corticosteroid therapy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlAutologous bone graftThe gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
TestAdvanced medicinal Therapy (MSC combined with biomaterial)Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
Primary Outcome Measures
NameTimeMethod
Change in bone width0-5 months

Changes in linear measurements of bone width measured by CBCT.Principal assessment is linear change in bone width 2 mm below alveolar crest measured by means of CBCT images from baseline to 5 months after the regenerative surgery, immediately prior to implant placement

Secondary Outcome Measures
NameTimeMethod
Pain postoperatively in the two different treatments21 months

Assessed by VAS scale, the scale goes from 0 to 100, 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable."

Radiological examination of bone volume21 months

To evaluate the formation of the new bone by assessing if it is possible to insert an implant in the reconstructed area 5 months after the grafting procedure. This decision will be made based on radiological examination of bone volume by means of 3D CBCT images captured immediately prior to implant placement, 5-6 months after the regenerative surgery.

Trial Locations

Locations (6)

Syddansk Universitet SDU (University Hospital of Southern Denmark)

🇩🇰

Odense, Denmark

Assistance Publique - Hôpitaux De Paris

🇫🇷

Créteil, France

CHU Nantes, Centre de Soins Dentaires

🇫🇷

Nantes, France

Universidad Complutense De Madrid

🇪🇸

Madrid, Calle Fernando De Castro Rodriguez,, Spain

Universitat Internacional De Catalunya

🇪🇸

Barcelona, Spain

University of Bergen, Institute of Clonical Dentistry

🇳🇴

Bergen, Hordaland, Norway

© Copyright 2025. All Rights Reserved by MedPath